World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 17 October 2023
Main ID:  JPRN-UMIN000001457
Date of registration: 28/10/2008
Prospective Registration: No
Primary sponsor: Division of Rheumatology & Clinical Immunology, Jichi Medical University
Public title: The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial
Scientific title: The efficacy evaluation of tocilizumab to glucocorticoid-resistant patients with adult Still's disease and systemic juvenile idiopathic arthritis: the open trial - Efficacy assessment of tocilizumab to steroid-resistant patients with adult Still's disease
Date of first enrolment: 2008/10/01
Target sample size: 10
Recruitment status: Complete: follow-up complete
URL:  https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001767
Study type:  Interventional
Study design:  Single arm Non-randomized  
Phase:  Not selected
Countries of recruitment
Japan
Contacts
Name:     Masahiro Iwamoto
Address:  3311-1 Yakushiji, Shimotsuke, Tochigi Japan
Telephone: 0285587358
Email: hiro-iwa@jichi.ac.jp
Affiliation:  Jichi Medical University Division of Rheumatology & Clinical Immunology
Name:     Masahiro Iwamoto
Address:  3311-1 Yakushiji, Shimotsuke, Tochigi Japan
Telephone: 0285587358
Email: hiro-iwa@jichi.ac.jp
Affiliation:  Jichi Medical University Division of Rheumatology & Clinical Immunology
Key inclusion & exclusion criteria
Inclusion criteria:
Exclusion criteria: 1.pregnant women or women trying to get pregnant 2.patients with dementia 3.patients considered inappropriate judged by attending physicians

Age minimum: 16years-old
Age maximum: Not applicable
Gender: Male and Female
Health Condition(s) or Problem(s) studied
Adult Still's disease and systemic juvenile idiopathic arthritis
Intervention(s)
Tocilizumab is to be infused every 2 to 4 weeks at 8 mg/kg of body weight
Primary Outcome(s)
Amount of glucocorticoid-dose tapered after tocilizumab-administration
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
None
Secondary Sponsor(s)
Ethics review
Status: YES
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed: 01/03/2013
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history